Synthesis of luminescent M2MoO5:Eu3+-MCM-41 (M: Ca2+, Sr2+, Ba2+) nanostructures with controlled drug release

Bortezomib ((1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazine-2-ylcarbonyl) amino] propanoyl} amino) butyl] boronic acid)is the first Proteosome inhibitör approved by US FDA for treatment of multiple myeloma and mantle cell lymphoma. It blocks NF-kB activation and causes apoptosis of various tumor cells and in many tumor models it reduces chemo and radioresistance dependent on nF-kB. Ibuprofen is a medicine used as antifebrile, anti-antiinflamatory and anelgesic agent. Its antifebrile effect continues for 2 to 4 hours after administration of the drug. However, since its solubility in water is low its bioavailability is limited and it is not stable in conventional chemotherapy. Therefore, it is necessary that new and efficient drug delivery systems are developed. Mesoporous silica structures are used in cntrolled drug delivery system. This material is modified so as to have luminescent property. This is important regarding its monitoring. However, the number of studies on this subject is limited and mesoporous MCM-41 structures modified with molybdates were not reported so far. In this study, new mesoporous M2MoO5:Eu3+-MCM-41 (M: Ca2+, Sr2+, Ba2+)nanostructures were prepared and Ibuprofen and Bortezomib were loaded onto them in supercritical carbondioxide (sC-CO2) medium. Thus prepared nanostructures were characterized via XRD and FT-IR. Their particle sizes and morphologies were investigated via SEM. Elemental analysis was performed by EDX. Thermal stability and drug loading of the nanostructures were investigated via DTA/TG techniques and drug release was investigated via UV-Vis spectrometry. The pore volumes of the nanostructures were determined via BET analysis. Luminsecent properties and release period were investigated via photoluminescence spectrometry.